Form 4: Fortress Biotech CEO Awarded 454,153 Restricted Shares

Fortress Biotech's CEO, Lindsay A. Rosenwald, received 454,153 restricted shares as part of the company's Long-Term Incentive Plan.

Summary

• Lindsay A. Rosenwald, the President, CEO, and Chairman of Fortress Biotech, Inc., was granted 454,153 restricted shares on January 1, 2025.
• These shares were awarded under the company's Long-Term Incentive Plan.
• The shares were granted at a price of $0.
• Following this transaction, Mr. Rosenwald directly owns 4,111,417 shares of Fortress Biotech common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative issues.

Positives

• The grant of restricted shares aligns the CEO's interests with the long-term performance of the company.
• The Long-Term Incentive Plan is being utilized to reward key executives.

Industry Context

The granting of restricted stock is a common practice in the biotech industry to incentivize and retain key executives, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation as a key component of executive pay packages.
• The size of the grant is not unusual for a CEO of a company of Fortress Biotech's size and stage.
• The use of a Long-Term Incentive Plan is a standard practice in the industry to encourage long-term value creation.

Stakeholder Impact

• The grant of restricted shares to the CEO could be viewed positively by shareholders as it aligns management's interests with the long-term performance of the company.
• The incentive plan may motivate the CEO to drive company growth and value.

Key Dates

Keywords

Fortress Biotech, restricted shares, Long-Term Incentive Plan, executive compensation, insider transaction, share ownership, Lindsay A. Rosenwald